Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans
Open Access
- 9 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (6) , 1144-1147
Abstract
Objectives: Activities in vitro of six antifungal agents were tested against a collection of 317 Cryptococcus neoformans var. neoformans clinical isolates. Methods: The procedure described in document 7.1 by the European Committee on Antibiotic Susceptibility Testing with minor modifications was employed. Results: Amphotericin B, itraconazole, voriconazole and ravuconazole exhibited a potent activity with geometric mean (GM) MICs under 0.26 mg/L. The GM MIC of flucytosine was 7.33 mg/L and that of fluconazole was 4.16 mg/L. The rates of antifungal resistance were 5.3% for amphotericin B, 0.9% for voriconazole and 3.1% for ravuconazole. Fifteen point eight per cent of strains had itraconazole MICs ≥1 mg/L, and 46% of strains had flucytosine MICs ≥8 mg/L. Fluconazole susceptibility (MIC ≤8 mg/L) stood at 53.4%. Conclusions: The percentage of fluconazole susceptibility was significantly lower than that in other surveys. Cross-resistance to itraconazole was common (33.8%) but almost the whole collection was susceptible to voriconazole and ravuconazole. These results should be confirmed with prospective and population-based surveillance programmes.Keywords
This publication has 13 references indexed in Scilit:
- International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and VoriconazoleJournal of Clinical Microbiology, 2005
- Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniquesClinical Microbiology and Infection, 2005
- Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)Journal of Clinical Microbiology, 2005
- In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast IsolatesAntimicrobial Agents and Chemotherapy, 2004
- Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002Journal of Antimicrobial Chemotherapy, 2004
- G484S Amino Acid Substitution in Lanosterol 14-α Demethylase ( ERG11 ) Is Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical IsolateAntimicrobial Agents and Chemotherapy, 2003
- Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeastsClinical Microbiology and Infection, 2003
- Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998Antimicrobial Agents and Chemotherapy, 2001
- Influence of Shaking on Antifungal Susceptibility Testing of Cryptococcus neoformans : a Comparison of the NCCLS Standard M27A Medium, Buffered Yeast Nitrogen Base, and RPMI–2% GlucoseAntimicrobial Agents and Chemotherapy, 2000
- Fluconazole tolerance in clinical isolates of Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 1997